Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 9/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297878 | 0.99 | TERT (0.75) | TERTALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4300594 | 0.86 | TERT (1.00) | TERTALDH1A1MAPT | |
| SCHEMBL9630438 | 0.86 | ALDH1A1 (0.64) | TERTALDH1A1POLBSMN1; SMN2KDM4E | |
| SCHEMBL8706439 | 0.86 | TERT (1.00) | TERTALDH1A1MAPT | |
| SCHEMBL3115635 | 0.86 | TERT (1.00) | TERTALDH1A1MAPT | |
| SCHEMBL8706042 | 0.86 | TERT (1.00) | TERTALDH1A1MAPT | |
| SCHEMBL9630688 | 0.86 | TERT (0.74) | TERTALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4289287 | 0.86 | TERT (0.74) | TERTALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4291737 | 0.86 | TERT (0.59) | TERTALDH1A1MAPT | |
| SCHEMBL4298492 | 0.84 | TERT (1.00) | TERTALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | TERT, NAT10, POT1 | TERT 1/4885ALDH1A1 481/4885MAPT 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.